Dr. Roman Shapiro, MD
Claim this profileDana-Farber Cancer Institute
Studies Myeloproliferative Disorder
Studies Acute Myelogenous Leukemia
4 reported clinical trials
8 drugs studied
Area of expertise
1Myeloproliferative Disorder
TP53 positive
Monosomy 7 positive
2Acute Myelogenous Leukemia
TP53 positive
Monosomy 7 positive
Affiliated Hospitals
Clinical Trials Roman Shapiro, MD is currently running
Inotuzumab Ozogamicin Post-Transplant
for Leukemia and Lymphoma
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
Recruiting1 award Phase 1 & 2
NK Cell Therapy
for Acute Myeloid Leukemia
The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. Names of the study therapies involved in this study are: * CIML NK cells intravenous infusion (cellular therapy) * Subcutaneous Interleukin-2 (recombinant, human glycoprotein)
Recruiting1 award Phase 110 criteria
More about Roman Shapiro, MD
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Roman Shapiro, MD has experience with
- Cytokine Induced Memory-like Natural Killer Cells
- Interleukin-2
- CIML NK
- Cyclophosphamide
- Fludarabine
- Abatacept
Breakdown of trials Roman Shapiro, MD has run
Myeloproliferative Disorder
Acute Myelogenous Leukemia
Myeloproliferative Neoplasms
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Roman Shapiro, MD specialize in?
Roman Shapiro, MD focuses on Myeloproliferative Disorder and Acute Myelogenous Leukemia. In particular, much of their work with Myeloproliferative Disorder has involved TP53 positive patients, or patients who are Monosomy 7 positive.
Is Roman Shapiro, MD currently recruiting for clinical trials?
Yes, Roman Shapiro, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Roman Shapiro, MD has studied deeply?
Yes, Roman Shapiro, MD has studied treatments such as Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2, CIML NK.
What is the best way to schedule an appointment with Roman Shapiro, MD?
Apply for one of the trials that Roman Shapiro, MD is conducting.
What is the office address of Roman Shapiro, MD?
The office of Roman Shapiro, MD is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.